Arrests, Investigations Over Vaccine Scandal in China

Changsheng is found to have forged records for a rabies vaccine and is accused of distributing thousands of substandard DPT immunizations to be used in children.

Written byKerry Grens
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Vaccine maker Changsheng fudged documentation on the quality of materials used in its rabies vaccine and violated the law, a Chinese government investigation has found. The conclusion comes as 15 people, including the chair of the company, are arrested on “suspicion of criminal offences,” Al Jazeera reports.

“The company used expired materials to produce some rabies vaccine and falsified the production date,” according to a government investigation cited by Reuters. “To cover up violations, the company systematically fabricated production and testing records.”

The fallout from the falsified records on the rabies vaccines comes amid news about another serious lapse by Changsheng in which it allegedly sold more than 250,000 doses of an ineffective diphtheria, pertussis, and tetanus (DPT) vaccine.

Problems emerged with Changsheng’s products last year, when China’s regulatory authority found the DPT vaccine to be subpar. Then this summer, Changsheng voluntarily recalled its rabies vaccine after admitting to falsifying ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies